Effects of using symbiotics in the clinical nutritional evolution of patients with chronic pancreatitis: Study prospective, randomized, controlled, double blind

Clinical Nutrition ESPEN

Volumn 18, Issue , 2017, Pages 9-15

  dos Santos, Patricia Quadros ^a   Guedes, Jorge C ^a   de Jesus, Rosangela P ^a   Santos, Raquel Rocha dos ^a   Fiaconne, Rosemeiri L ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Chronic pancreatitis; Intestinal pace; Nutritional status; Symbiotics

Indexed keywords

FRUCTOSE OLIGOSACCHARIDE; HEMOGLOBIN; MALTODEXTRIN; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; SYMBIOTIC AGENT; UNCLASSIFIED DRUG; CHOLESTEROL; PROBIOTIC AGENT;

ADIPOSE TISSUE; ADULT; ARM CIRCUMFERENCE; ARTICLE; BIFIDOBACTERIUM BIFIDUM; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; CHRONIC PANCREATITIS; COLONY FORMING UNIT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; IMPEDANCE; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; LYMPHOCYTE COUNT; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUSCLE MASS; NUTRITIONAL STATUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; BLOOD; INTESTINE FLORA; TREATMENT OUTCOME;

ADULT; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; MALE; NUTRITIONAL STATUS; PANCREATITIS, CHRONIC; PROBIOTICS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85013393549     PISSN: 24054577     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnesp.2017.01.005     Document Type: Article

References (38)

1. [1] Schreyer, A.J., Jung, M., Riemann, J.F., Niessen, C., Pregler, B., Grenacher, L., et al. Guideline for chronic pancreatites – diagnosis, classification and therapy for the radiologist. Fortschr Rõntgenstr, 2014.
2. [2] Frangella, V.S., Silva, C.S., Cuidados nutricionais na pancreatite crônica: uma atualização. Rev mundo saúde São Paulo 33:1 (2009), 73–79.
3. [3] Dominguez-Muñoz, J.E., Latest advances in chronic pancreatitis. Gastroenterol Hepatol, 2013, 86–89.
4. [4] Meier, R., Ockenga, J., Pertkiewicz, M., Pap, A., Milinic, N., Macfie, J., et al. ESPEN guidelines on enteral: pâncreas. Rev Clin Nutr 25 (2006), 275–284.
5. [5] Witt, H., Apte, M.V., Keim, V., Wilson, J.S., Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy. Gastroenterology 132 (2007), 1557–1573.
6. [6] WGO (World Gastroenterology Organisation), WGO practice guidelines: malabsorption. 2008 Disponível em: http://www.worldgastroenterology.org/assets/downloads/en/pdf/guidelines/13_malabsorption_en.pdf [Acesso: Janeiro de 2014].
7. [7] Oliveira, L.C.M., Santos, J.F.G., Rocha, A., Prevalência da pancreatite crônica em pacientes portadores de cirrose hepática alcoólica: estudo histopatológico. J Bras Patol Med Lab 43:2 (2007), 115–120.
8. [8] Damaskos, D., Kollos, G., Probiotics end prebiotics in inflammatory bowel disease: microflora “on the scope”. Br J Clin Pharmacol 65:4 (2008), 456–467.
9. [9] Sociedade Brasileira de Nutrição Parenteral e Enteral, Associação Brasileira de Nutrologia, Terapia Nutricional na Pancreatite Crônica. 2011 Disponível em: http://www.projetodiretrizes.org.br/9_volume/terapia_nutricional_na_pancreatite_cronica.pdf [Acesso: Janeiro de 2014].
10. [10] Singh, S., Midha, S., Singh, N., Joshi, Y.K., Garg, P.K., Dietary counseling versus dietary supplements for malnutrition in chronic pancreatitis: a randomized controlled trial. Clin Gastroenterol Hepatol 6:3 (2008), 353–359.
11. [11] Floch, M.H., Walker, W.A., Guandalini, S., Hibberd, P., Gorbach, S., Surawicz, C., et al. Recommendations for probiotic use – 2008. J Clin Gastroenterol 2:42 (2008), 104–108.
12. [12] Raizel, R., Santini, E., Kopper, A.M., Filho, A.D.R., Efeitos do consumo de probióticos, prebióticos e simbióticos para o organismo humano. Revista Ciencias Saúde 4:2 (2011), 66–74.
13. [13] Grinevich, V.B., Sas, E.I., Denisov, N.L., Efimov, O.I., Chronic pancreatitis: microbe-intestinal tissue complex and systemic inflammatory response. Eksp Klin Gastroenterol 7 (2011), 13–17.
14. [14] Renhe, I.R.T., Volp, A.C., Barbosa, K.B.F., Stringheta, P.C., Prebióticos e os Benéficios de seu Consumo na Saúde. Rev Bras Nutr Clínica 23:2 (2008), 119–126.
15. [15] Saad, S.M.I., Probiótico e Prebiótico: o estado da arte. Rev Bras Ciências Farm 42 (2006), 01–16.
16. [16] Vrese, M., Schrezenmeir, J., Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol 111 (2008), 1–66.
17. [17] Theodorou, V., Belgnaoui, A.A., Agostini, S., Eutamene, H., Effect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome. Gut Microbes 5:3 (2014), 430–436.
18. [18] Dylag, K., Hubalewska-Mazgaj, M., Surmiak, M., Szmyd, J., Brzozowski, T., Probiotics in the mechanism of protection against gut inflammation and therapy of gastrointestinal disorders. Curr Pharm Des 20:7 (2014), 1149–1155.
19. [19] Roberfroid, M., Gibson, G.R., Hoyles, L., McCartney, A.L., Rastall, R., Rowland, I., et al. Prebiotic effects: metabolic and health benefits. Br J Nutr 104:Suppl 2 (2010), S1–S63.
20. [20] Barrenetxe, J., Aranguren, P., Grijalba, A., Martínez-Peñuela, J.M., Marzo, F., Urdaneta, E., Modulacion de La fisiologia gastrointestinal mediante cepas probióticas de Lactobacillus casei y Bifidobacterium bifidum. An del Sist Sanit Navar 29:3 (2006), 337–346.
21. [21] Lohman, T.G., Roche, A.F., Martorell, R., Anthropometric standardization reference manual. Abridged edition. 1991 90p.
22. [22] Sampaio, L.R., Kamimura, M.A., Avaliação Nutricional na Prática Clínica. Cuppari, Lilian, (eds.) Nutrição nas Doenças Crônicas não Transmissíveis, 1st ed., 2009, Manole, São Paulo, 27–70.
23. [23] Scheunemann, L., Wazlawik, E., Trindade, E.B.S.M., Aplicação do ângulo de fase na prática clínica nutricional. Revista Brasileira de Nutrição Clínica 23:4 (2008), 292–297.
24. [24] Silva, L.M.D.L., Caruso, L., Martini, L.A., Aplicação do ângulo de fase em situações clínicas. Revista Brasileira de Nutrição Clínica 22:4 (2007), 317–321.
25. [25] Diggle, P.J., Heagerty, P., Kung-Yee, L., Zeger, S.L., Analysis of longitudinal data. 2nd ed., 2002, Oxford University Press, Oxford, United Kingdom 379p.
26. [26] Fundação Antonio Prudente: Centro de Tratamento e Pesquisa do Hospital do Câncer. Dor – Mensuração, Janeiro de 2002 Disponível http://www.saudeemmovimento.com.br/conteudos/conteudo_print.asp?cod_noticia=39#grandeAcesso Janeiro de 2009.
27. [27] Pezzilli, R., Chronic pancreatitis: maldigestion, intestinal ecology and intestinal inflammation. World J Gastroenterol 15:14 (2009), 1673–1676.
28. [28] Santos, R.R., Guedes, J.C., Mello, A.L., Santana, G.O., Lyra, L.G., Consumo protéico e de etanol entre pacientes com pancreatite crônica em Salvador, Bahia: estudo descritivo de 21 casos. GED – Gastroenterologia e Endoscopia Digestiva 22:4 (2003), 123–128.
29. [29] Guyonnet, D., Chassany, O., Ducrotte, P., Picard, C., Mouret, M., Mercier, C.H., et al. Effect of a fermented Milk containing Bifidobacterium animalis DN – 173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-dlind, controlled trial. Aliment Pharmacol Ther 26 (2007), 475–486.
30. [30] Sabater-Molina, M., Larqué, E., Torrella, F., Zamora, S., Dietary fructooligosaccharides and potential benefits on health. J Physiol Biochem 65:3 (2009), 315–328.
31. [31] Nascimento, T.V.N., Cardoso, M.V., Santos, P.Q., Guedes, J.C., Características Etiológicas e Clínicas da Pancreatite Crônica em pacientes da Bahia. In: VII Semana Brasileira do Aparelho Digestivo, 2006, SP. GED – Gastroenterologia e Endoscopia Digestiva, 25, 2006, 20.
32. [32] Flesch, A.G., Poziomyck AK, Damin DC, O uso terapêutico dos simbióticos. ABCD Arq Bras Cir Dig 27:3 (2014), 206–209.
33. [33] Hongling, L., Changcheng, W., Shuqing, L., Dongsheng, X., Zhang, J., Hongmei, C., Relationship between chronic diarrhea with normal colonoscopy findings and terminal ileum lesions. Chin Med J 127:16 (2014), 2915–2917.
34. [34] Zheng, S., Steenhout, P., Kuiran, D., Qihong, W., Weiping, W., Hager, C., et al. Nutritional support of pediatric patients with cancer consuming an enteral formula with fructooligosaccharides. Nutr Res 26 (2006), 154–162.
35. [35] Legette, L.L., Lee, W., Martin, B.R., Story, J.A., Campbell, J.K., Weaver, C.M., Prebiotics enhance magnesium absorption and inulin-based fibers exert chronic effects on calcium utilization in a postmenopausal rodent model. J Food Sci. 77:4 (2012), 88–94.
36. [36] Morrow, L.E., Gogineni, V., Malesker, M.A., Probiotic, prebiotic, and synbiotic use in critically ill patients. Curr Opin Crit Care 18:2 (2012), 186–191.
37. [37] Varley, P.F., McCarney, C., Callan, J.J., O'Doherty, J.V., Effect of dietary mineral level and inulin inclusion on phosphorus, calcium and nitrogen utilisation, intestinal microflora and bone development. J Sci Food Agric 90:14 (2010), 2447–2454.
38. [38] Dora, I.A., Pereira, G.R., Effects of Consumption of Probiotics and Prebiotics on Serum Lipid Levels in Humans. Crit Rev Biochem Mol Biol 37:4 (2002), 259–281.